Established in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research and development and manufacturing. The company has two business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services. The company’s product portfolio covers a wide spectrum of pharmaceutical formulations in various therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic agents, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. The company’s customer base comprises central and state government departments, pharmaceutical companies, public and private sector hospitals, and super stockists across India. Sai Parenteral’s started its export business in FY 2023 after acquiring two international accredited facilities in Hyderabad, Telangana, and currently serves regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, Middle East, and Africa. The company has five manufacturing facilities in India. Four are located in Hyderabad, Telangana. These are a GMP compliant injectable facility, a WHO-GMP injectable facility, a TGA-Australia and PIC/S accredited solid oral dosage facility, and a WHO-GMP cephalosporin facility. The company’s wholly owned subsidiary has a GMP certified facility located in Ongole, Andhra Pradesh. As of August 31, 2025, Sai Parenteral's Ltd. had 277 full-time employees.